Rush University Medical Center-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2008

  1. The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent. The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

    Journal of the American College of Cardiology, Vol. 51, Núm. 17, pp. 1632-1641

2006

  1. Insulin resistance, hyperinsulinemia, and renal injury: Mechanisms and implications

    American Journal of Nephrology, Vol. 26, Núm. 3, pp. 232-244

  2. Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: The IMPROVE trial

    Journal of Human Hypertension, Vol. 20, Núm. 9, pp. 693-700

  3. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

    Journal of Hypertension, Vol. 24, Núm. 10, pp. 2047-2055

2005

  1. Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection

    Blood Pressure, Vol. 14, Núm. 4, pp. 196-209

2004

  1. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en Dlabéticos tipo Dos) study

    Journal of Hypertension, Vol. 22, Núm. 1, pp. 217-222

2002

  1. Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (opera) trial

    American Journal of Hypertension, Vol. 15, Núm. 2 I, pp. 193-198